Skip to main content

RX Updates

Long Term JaK Inhibitor Thumbnail

Long-term JAK Inhibitor Treatment for Psoriatic Arthritis (PsA)

Sponsored by AbbVie Medical Affairs
Read for an overview of long-term results from SELECT-PsA 2, a clinical trial of oral upadacitinib vs. placebo in bDMARD-refractory PsA patients.
An Anti-IL-23 in Active Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis

An Anti-IL-23 in Active Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis

Sponsored by Janssen Biotech, Inc
Plaque psoriasis (PsO) and psoriatic arthritis (PsA) are disorders of the immune system driven primarily by dysregulated T cells. Studies suggest that the Interleukin (IL)-23/Th-17 axis is one of the pathways involved in the pathogenesis of PsO and PsA.
Expert Perspectives on SLE Pathophysiology and the Importance of Changing the Course of Disease

Expert Perspectives on SLE Pathophysiology and the Importance of Changing the Course of Disease

Sponsored by GSK US Medical Affairs
Leading experts from the SLE Educators' Network take us through the pathophysiology of SLE as we understand it today, and discuss the need to change the course of disease as a key treatment goal.
The Science Behind a JAK Inhibitor for the Treatment of Ankylosing Spondylitis(AS)

The Science Behind a JAK Inhibitor for the Treatment of Ankylosing Spondylitis(AS)

Sponsored by AbbVie Medical Affairs
Read for an overview of results from SELECT-AXIS 2, a clinical trial of oral upadacitinib vs. placebo in bDMARD-refractory AS patients.
PsA All the Way

The Future of PsA

RheumNow
As we conclude our PsA campaign, Dr. Ogdie shares information about Preventing PsA and Dr. Ritchlin discusses Future Discovery and Targets.
PsA Thumbnail

Secukinumab in patients with Psoriatic Arthritis and Axial Manifestation

Sponsored by Novartis
Secukinumab in patients with Psoriatic Arthritis and Axial Manifestation: results from the double-blind, randomised, phase 3 MAXIMISE trial.
Long-Term Safety Profile of Secukinumab: Analysis of Malignancies Up to 5 Years of Exposure Across Indications

Long-Term Safety Profile of Secukinumab: Analysis of Malignancies Up to 5 Years of Exposure Across Indications

Sponsored by Novartis Medical Affairs
The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and postmarketing surveillance data with up to five years of follow-up.
Role of Risankizumab-rzaa

The Role of a Selective IL-23 p19 inhibitor for Patients with Psoriatic Arthritis

Sponsored by AbbVie Medical Affairs
Psoriatic arthritis is heterogeneous in symptoms and severity. A selective IL-23 p19 inhibitor with a 12-week maintenance dosing interval is approved for adults with active PsA
Long-Term Safety Profile of Secukinumab: Analysis of Malignancies Up to 5 Years of Exposure Across Indications

Long-Term Safety Profile of Secukinumab: Analysis of Malignancies Up to 5 Years of Exposure Across Indications

Sponsored by Novartis Medical Affairs
The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and postmarketing surveillance data with up to five years of follow-up.
The Science of Upadacitinicib in Psoriatic Arthritis

The Science of Upadacitinib in Psoriatic Arthritis

Sponsored by AbbVie Medical Affairs
Cardiovascular events

Comorbidities in axSpA: A Focus on Cardiovascular Features

Sponsored by Novartis Medical Affairs
Patients with axial spondyloarthritis (axSpA) commonly experience cardiovascular (CV) comorbidities. There is a need to holistically assess a patient, including considerations for managing disease activity and understanding the safety profile of available therapies as it relates to comorbidities. Join Marina Magrey, MD as she provides insight on this topic for holistic patient-centered care.
Juvenile-Psoriatic Arthritis Rx Update

Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-Related Arthritis (ERA): Current Challenges and Future Outlook

Sponsored by Novartis Medical Affairs
There is a significant burden of disease associated with JPsA and ERA, with patients experiencing structural damage progression, risk of disability, and comorbidities that may persist into adulthood. This presentation led by Hermine Brunner, MD educates on the importance of early recognition and management.
×